It's serious plavix other names SAC's report to employees said the sale was made based on Mr. Martoma's "recommendation to reduce SAC's exposure on a position that had appreciated approximately 40% over the previous six weeks." The report added that "most knowledgeable observers believed" the position had little further short-term upside, and selling "at a time of volatile and declining general market trends, was perfectly reasonable." Prosecutors charged Mr. Martoma last year with fraud and conspiracy related to trading in the two health-care stocks. He pleaded not guilty and is set to go on trial in November.
|